Giovannini, C.; Suzzi, F.; Tovoli, F.; Bruccoleri, M.; Marseglia, M.; Alimenti, E.; Fornari, F.; Iavarone, M.; Piscaglia, F.; Gramantieri, L.
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma. Cancers 2023, 15, 1661.
https://doi.org/10.3390/cancers15061661
AMA Style
Giovannini C, Suzzi F, Tovoli F, Bruccoleri M, Marseglia M, Alimenti E, Fornari F, Iavarone M, Piscaglia F, Gramantieri L.
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma. Cancers. 2023; 15(6):1661.
https://doi.org/10.3390/cancers15061661
Chicago/Turabian Style
Giovannini, Catia, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, and Laura Gramantieri.
2023. "Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma" Cancers 15, no. 6: 1661.
https://doi.org/10.3390/cancers15061661
APA Style
Giovannini, C., Suzzi, F., Tovoli, F., Bruccoleri, M., Marseglia, M., Alimenti, E., Fornari, F., Iavarone, M., Piscaglia, F., & Gramantieri, L.
(2023). Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma. Cancers, 15(6), 1661.
https://doi.org/10.3390/cancers15061661
